1. Home
  2. WT vs MESO Comparison

WT vs MESO Comparison

Compare WT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WisdomTree Inc.

WT

WisdomTree Inc.

HOLD

Current Price

$18.37

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.72

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WT
MESO
Founded
1985
2004
Country
United States
Australia
Employees
N/A
81
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
WT
MESO
Price
$18.37
$16.72
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$17.33
N/A
AVG Volume (30 Days)
3.3M
276.9K
Earning Date
05-01-2026
02-26-2026
Dividend Yield
0.69%
N/A
EPS Growth
127.27
N/A
EPS
0.75
N/A
Revenue
$493,753,000.00
N/A
Revenue This Year
$35.04
$629.74
Revenue Next Year
$8.68
$30.65
P/E Ratio
$23.27
N/A
Revenue Growth
15.43
N/A
52 Week Low
$8.18
$9.88
52 Week High
$17.87
$21.50

Technical Indicators

Market Signals
Indicator
WT
MESO
Relative Strength Index (RSI) 70.09 61.29
Support Level $13.07 $14.44
Resistance Level N/A $17.89
Average True Range (ATR) 0.74 0.53
MACD 0.37 0.29
Stochastic Oscillator 96.85 93.92

Price Performance

Historical Comparison
WT
MESO

About WT WisdomTree Inc.

WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: